Biomarker-oriented chemo-immunotherapy for advanced gastric cancer.

Authors :: Kono K
Nakajima S
Mimura K
Source :: International journal of clinical oncology [Int J Clin Oncol] 2024 Jul; Vol. 29 (7), pp. 865-872. Date of Electronic Publication: 2024 Apr 22.
Publication Year :: 2024
Abstract: The biomarker-oriented chemo-immunotherapy is useful and promising in the development of new anticancer agents, since the responders can be enriched by selecting patients with biomarkers. Compared to colorectal and lung cancers, the development of biomarker-driven molecular-targeted therapeutics for gastric cancers has been straggled. However, several new biomarkers in gastric cancers have been discovered and clinical trials in enrichment design with certain biomarkers have been conducted. Therefore, there are currently several treatment options to treat gastric cancer patients based on individual biomarker-oriented strategies. In the present review, we describe the useful biomarkers in gastric cancer, with focusing on HER2, PD-L1, and Claudin18.2, in relation to their clinical significance and associated targeted agents.<br /> (© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)